SN2426

Open to Accrual

Return to Protocol Table

Use Tab key to navigate between tabs, Enter or Space to activate a tab, and arrow keys to move between tabs.

SWOG SN2426/NRG-HN013 Joint Study: A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma

Principal Investigator

Jessica Geiger

Status

Open to Accrual

Date Opened To Accrual

January 28, 2026

Disease Site

Head and Neck [HN] Other

Phase

Developmental Therapeutics

Primary Objective

Safety run-in (Cohort A): To evaluate the safety and preliminary efficacy of amivantamab monotherapy in patients with locoregionally incurable or metastatic cutaneous squamous cell carcinoma and an active immunosuppressed condition

Randomized comparison (Cohort B): To compare progression-free survival (PFS) of amivantamab monotherapy versus cetuximab monotherapy in patients with locoregionally incurable or metastatic cutaneous squamous cell carcinoma and an active immunosuppressed condition

NOTE:

This is a Joint SWOG & NRG Oncology trial. NRG Oncology institutions can credit NRG for their case accrual.

SWOG PI: Paul L. Swiecicki, M.D

Patient Population

Patients with recurrent inoperable or metastatic cutaneous squamous cell carcinoma

Target Accrual

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.

Protocol Information